schliessen

Filtern

 

Bibliotheken

Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus

Byline: Litsa Nikitidou, Malene Torp, Lone Fjord-Larsen, Philip Kusk, Lars U. Wahlberg, Merab Kokaia Keywords: Galanin; Epilepsy; Kindling; Hippocampus; Encapsulated cells; ECB device Summary Purpose Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed... Full description

Journal Title: Epilepsia Jan, 2014, Vol.55(1), p.167(8)
Main Author: Nikitidou, Litsa
Other Authors: Torp, Malene , Fjord - Larsen, Lone , Kusk, Philip , Wahlberg, Lars U. , Kokaia, Merab
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0013-9580
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_hrca356157763
title: Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus
format: Article
creator:
  • Nikitidou, Litsa
  • Torp, Malene
  • Fjord - Larsen, Lone
  • Kusk, Philip
  • Wahlberg, Lars U.
  • Kokaia, Merab
subjects:
  • Electroencephalography -- Analysis
  • Electroencephalography -- Health Aspects
  • Cells (Biology) -- Analysis
  • Cells (Biology) -- Health Aspects
  • Seizures (Medicine) -- Analysis
  • Seizures (Medicine) -- Health Aspects
  • Brain -- Analysis
  • Brain -- Health Aspects
  • Neuropeptides -- Analysis
  • Neuropeptides -- Health Aspects
  • Enzyme-linked Immunosorbent Assay -- Analysis
  • Enzyme-linked Immunosorbent Assay -- Health Aspects
  • Genetically Modified Organisms -- Analysis
  • Genetically Modified Organisms -- Health Aspects
  • Glutamate -- Analysis
  • Glutamate -- Health Aspects
  • Epilepsy -- Analysis
  • Epilepsy -- Health Aspects
ispartof: Epilepsia, Jan, 2014, Vol.55(1), p.167(8)
description: Byline: Litsa Nikitidou, Malene Torp, Lone Fjord-Larsen, Philip Kusk, Lars U. Wahlberg, Merab Kokaia Keywords: Galanin; Epilepsy; Kindling; Hippocampus; Encapsulated cells; ECB device Summary Purpose Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures. Methods Two clones from a genetically modified human cell line secreting different levels of galanin were tested. Electroencephalography (EEG) recordings and stimulations were performed by electrodes implanted into the hippocampus at the same surgical session as ECB devices. One week after the surgery, rapid kindling stimulations were initiated. Key Findings Enzyme-linked immunosorbent assay (ELISA) measurements prior to device implantation showed a release of galanin on average of 8.3 ng/mL/24 h per device for the low-releasing clone and 12.6 ng/mL/24 h per device for the high-releasing clone. High-releasing galanin-producing ECB devices moderately decreased stimulation-induced focal afterdischarge duration, whereas low-releasing ECB devices had no significant effect. Significance Our study shows that galanin-releasing ECB devices moderately suppress focal stimulation-induced recurrent seizures. Despite this moderate effect, the study provides conceptual proof that ECB could be a viable alternative approach to cell therapy in humans, with the advantage that the treatment could be terminated by removing these devices from the brain. Thereby, this strategy provides a higher level of safety for future therapeutic applications, in which genetically modified human cell lines that are optimized to produce and release antiepileptic compounds could be clinically evaluated for their seizure-suppressant effects. A PowerPoint slide summarizing this article is available for dow
language: English
source:
identifier: ISSN: 0013-9580
fulltext: fulltext
issn:
  • 0013-9580
  • 00139580
url: Link


@attributes
ID100607444
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid356157763
sourceidgale_hrca
recordidTN_gale_hrca356157763
sourceformatXML
sourcesystemOther
galeid356157763
display
typearticle
titleEncapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus
creatorNikitidou, Litsa ; Torp, Malene ; Fjord - Larsen, Lone ; Kusk, Philip ; Wahlberg, Lars U. ; Kokaia, Merab
ispartofEpilepsia, Jan, 2014, Vol.55(1), p.167(8)
identifierISSN: 0013-9580
subjectElectroencephalography -- Analysis ; Electroencephalography -- Health Aspects ; Cells (Biology) -- Analysis ; Cells (Biology) -- Health Aspects ; Seizures (Medicine) -- Analysis ; Seizures (Medicine) -- Health Aspects ; Brain -- Analysis ; Brain -- Health Aspects ; Neuropeptides -- Analysis ; Neuropeptides -- Health Aspects ; Enzyme-linked Immunosorbent Assay -- Analysis ; Enzyme-linked Immunosorbent Assay -- Health Aspects ; Genetically Modified Organisms -- Analysis ; Genetically Modified Organisms -- Health Aspects ; Glutamate -- Analysis ; Glutamate -- Health Aspects ; Epilepsy -- Analysis ; Epilepsy -- Health Aspects
languageEnglish
source
descriptionByline: Litsa Nikitidou, Malene Torp, Lone Fjord-Larsen, Philip Kusk, Lars U. Wahlberg, Merab Kokaia Keywords: Galanin; Epilepsy; Kindling; Hippocampus; Encapsulated cells; ECB device Summary Purpose Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures. Methods Two clones from a genetically modified human cell line secreting different levels of galanin were tested. Electroencephalography (EEG) recordings and stimulations were performed by electrodes implanted into the hippocampus at the same surgical session as ECB devices. One week after the surgery, rapid kindling stimulations were initiated. Key Findings Enzyme-linked immunosorbent assay (ELISA) measurements prior to device implantation showed a release of galanin on average of 8.3 ng/mL/24 h per device for the low-releasing clone and 12.6 ng/mL/24 h per device for the high-releasing clone. High-releasing galanin-producing ECB devices moderately decreased stimulation-induced focal afterdischarge duration, whereas low-releasing ECB devices had no significant effect. Significance Our study shows that galanin-releasing ECB devices moderately suppress focal stimulation-induced recurrent seizures. Despite this moderate effect, the study provides conceptual proof that ECB could be a viable alternative approach to cell therapy in humans, with the advantage that the treatment could be terminated by removing these devices from the brain. Thereby, this strategy provides a higher level of safety for future therapeutic applications, in which genetically modified human cell lines that are optimized to produce and release antiepileptic compounds could be clinically evaluated for their seizure-suppressant effects. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here. Supporting information: Additional Supporting Information may be found in the online version of this article CAPTION(S):
version2
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Nikitidou, Litsa
1Litsa Nikitidou
2Torp, Malene
3Fjord-Larsen, Lone
4Kusk, Philip
5Wahlberg, Lars U
6Kokaia, Merab
titleEncapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.
subject
0Electroencephalography--Analysis
1Electroencephalography--Health aspects
2Cells (Biology)--Analysis
3Cells (Biology)--Health aspects
4Seizures (Medicine)--Analysis
5Seizures (Medicine)--Health aspects
6Brain--Analysis
7Brain--Health aspects
8Neuropeptides--Analysis
9Neuropeptides--Health aspects
10Enzyme-linked immunosorbent assay--Analysis
11Enzyme-linked immunosorbent assay--Health aspects
12Genetically modified organisms--Analysis
13Genetically modified organisms--Health aspects
14Glutamate--Analysis
15Glutamate--Health aspects
16Epilepsy--Analysis
17Epilepsy--Health aspects
general
0English
1Wiley Subscription Services, Inc.
2Cengage Learning, Inc.
sourceidgale_hrca
recordidgale_hrca356157763
issn
00013-9580
100139580
rsrctypearticle
creationdate2014
recordtypearticle
addtitleEpilepsia
searchscopegale_hrca
scopegale_hrca
lsr30VSR-Enriched:[description, galeid]
sort
titleEncapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.
authorNikitidou, Litsa ; Torp, Malene ; Fjord - Larsen, Lone ; Kusk, Philip ; Wahlberg, Lars U. ; Kokaia, Merab
creationdate20140101
facets
frbrgroupid7780781649882653846
frbrtype5
languageeng
creationdate2014
topic
0Electroencephalography–Analysis
1Electroencephalography–Health Aspects
2Cells (Biology)–Analysis
3Cells (Biology)–Health Aspects
4Seizures (Medicine)–Analysis
5Seizures (Medicine)–Health Aspects
6Brain–Analysis
7Brain–Health Aspects
8Neuropeptides–Analysis
9Neuropeptides–Health Aspects
10Enzyme-linked Immunosorbent Assay–Analysis
11Enzyme-linked Immunosorbent Assay–Health Aspects
12Genetically Modified Organisms–Analysis
13Genetically Modified Organisms–Health Aspects
14Glutamate–Analysis
15Glutamate–Health Aspects
16Epilepsy–Analysis
17Epilepsy–Health Aspects
collectionHealth Reference Center Academic (Gale)
prefilterarticles
rsrctypearticles
creatorcontrib
0Nikitidou, Litsa
1Torp, Malene
2Fjord - Larsen, Lone
3Kusk, Philip
4Wahlberg, Lars U.
5Kokaia, Merab
jtitleEpilepsia
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Nikitidou, Litsa
1Torp, Malene
2Fjord-Larsen, Lone
3Kusk, Philip
4Wahlberg, Lars U.
5Kokaia, Merab
atitleEncapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.
jtitleEpilepsia
risdate20140101
volume55
issue1
spage167
issn0013-9580
genrearticle
ristypeJOUR
pubWiley Subscription Services, Inc.
lad01gale_hrca
date2014-01-01